アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - ribavirin (unii: 49717awg6k) (ribavirin - unii:49717awg6k) - ribavirin 6 g - ribavirin for inhalation solution, usp is indicated for the treatment of hospitalized infants and young children with severe lower respiratory tract infections due to respiratory syncytial virus. treatment early in the course of severe lower respiratory tract infection may be necessary to achieve efficacy. only severe rsv lower respiratory tract infection should be treated with ribavirin for inhalation solution, usp. the vast majority of infants and children with rsv infection have disease that is mild, self-limited, and does not require hospitalization or antiviral treatment. many children with mild lower respiratory tract involvement will require shorter hospitalization than would be required for a full course of ribavirin for inhalation solution, usp aerosol (3 to 7 days) and should not be treated with the drug. thus the decision to treat with ribavirin for inhalation solution, usp should be based on the severity of the rsv infection. the presence of an underlying condition such as prematurity, immunosuppr

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

zydus lifesciences limited - ribavirin (unii: 49717awg6k) (ribavirin - unii:49717awg6k) - ribavirin 200 mg - ribavirin tablets in combination with peginterferon alfa-2a are indicated for the treatment of patients 5 years of age and older with chronic hepatitis c (chc) virus infection who have compensated liver disease and have not been previously treated with interferon alpha. the following points should be considered when initiating ribavirin tablets combination therapy with peginterferon alfa-2a: - this indication is based on clinical trials of combination therapy in patients with chc and compensated liver disease, some of whom had histological evidence of cirrhosis (child-pugh class a), and in adult patients with clinically stable hiv disease and cd4 count greater than 100 cells/mm3 . - this indication is based on achieving undetectable hcv rna after treatment for 24 or 48 weeks, based on hcv genotype, and maintaining a sustained virologic response (svr) 24 weeks after the last dose. - safety and efficacy data are not available for treatment longer than 48 weeks. - the safe

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

zydus lifesciences limited - ribavirin (unii: 49717awg6k) (ribavirin - unii:49717awg6k) - ribavirin 200 mg - ribavirin capsules in combination with interferon alfa-2b (pegylated and nonpegylated) is indicated for the treatment of chronic hepatitis c (chc) in patients 3 years of age and older with compensated liver disease [see warnings and precautions (5.9, 5.10), and use in specific populations (8.4)]. the following points should be considered when initiating ribavirin capsules combination therapy with pegintron® or intron a® : - combination therapy with ribavirin /pegintron is preferred over ribavirin /intron a as this combination provides substantially better response rates [see clinical studies (14) ]. - patients with the following characteristics are less likely to benefit from retreatment after failing a course of therapy: previous nonresponse, previous pegylated interferon treatment, significant bridging fibrosis or cirrhosis, and genotype 1 infection [see clinical studies (14) ]. - no safety and efficacy data are available for treatment duration lasting longer than one year. ribavirin capsules combination

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

gland pharma limited - tirofiban hydrochloride (unii: 6h925f8o5j) (tirofiban - unii:ggx234si5h) - tirofiban hydrochloride injection is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-st elevation acute coronary syndrome (nste-acs). tirofiban hydrochloride injection is contraindicated in patients with: - severe hypersensitivity reaction to tirofiban hydrochloride injection (i.e.,anaphylactic reactions) [see adverse reactions (6.2)]. - a history of thrombocytopenia following prior exposure to tirofiban hydrochloride injection [see adverse reactions (6.1)]. - active internal bleeding or a history of bleeding diathesis, major surgical procedure or severe physical trauma within the previous month [see adverse reactions (6.1)]. risk summary while published data cannot definitively establish the absence of risk, available published case reports have not established an association with tirofiban use during pregnancy and major birth defects, miscarriage, or adverse maternal or

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

clinect pty ltd - ribavirin -

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

clinect pty ltd - ribavirin -

イギリス - 英語 - myHealthbox

milpharm limited - ribavirin - capsule, hard - 200mg - direct acting antivirals, nucleosides and nucleotides (excl.reverse transcriptase inhibitors) - adult patients: ribavirin is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis c except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (alt), who are positive for hepatitis c viral ribonucleic acid hcv-rna children 3 years of age and older and adolescents: ribavirin is intended for use, in a combination regimen with interferon alfa-2b, for the treatment of children and adolescents 3 years of age and older, who have all types of chronic hepatitis c, except genotype 1, not previously treated, without liver decompensation, and who are positive for hcv-rna. when deciding to not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition. the reversibility of growth inhibition is uncertain. the decision to treat should be made on a case by case basis

欧州連合 - 英語 - EMA (European Medicines Agency)

teva b.v. - ribavirin - hepatitis c, chronic - antivirals for systemic use - ribavirin teva pharma b.v. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis c (chc) in adults (see sections 4.2, 4.4, and 5.1).ribavirin teva pharma b.v. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis c (chc) for paediatric patients (children 3 years of age and older and adolescents) notpreviously treated and without liver decompensation (see sections 4.2, 4.4 and 5.1).

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

shionogi inc. - doripenem (unii: bhv525jobh) (doripenem - unii:bhv525jobh) - doripenem 500 mg in 10 ml - doribax ® (doripenem for injection) is indicated as a single agent for the treatment of complicated intra-abdominal infections caused by escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, bacteroides caccae, bacteroides fragilis, bacteroides thetaiotaomicron, bacteroides uniformis, bacteroides vulgatus, streptococcus intermedius, streptococcus constellatus and peptostreptococcus micros . doribax ® (doripenem for injection) is indicated as a single agent for the treatment of complicated urinary tract infections, including pyelonephritis caused by escherichia coli including cases with concurrent bacteremia, klebsiella pneumoniae , proteus mirabilis , pseudomonas aeruginosa ,  and acinetobacter baumannii . to reduce the development of drug-resistant bacteria and maintain the effectiveness of doribax ® and other antibacterial drugs, doribax ® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility infor

欧州連合 - 英語 - EMA (European Medicines Agency)

janssen-cilag international nv - doripenem - pneumonia, ventilator-associated; pneumonia, bacterial; urinary tract infections; bacterial infections; cross infection - antibacterials for systemic use, - doribax is indicated for the treatment of the following infections in adults:nosocomial pneumonia (including ventilator-associated pneumonia);complicated intra-abdominal infections;complicated urinary tract infections.consideration should be given to official guidance on the appropriate use of antibacterial agents.